XM does not provide services to residents of the United States of America.
C
C

Church&Dwight

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. Crown Holdings, Waters, West Pharmaceutical Service

U.S. RESEARCH ROUNDUP-Crown Holdings, Waters, West Pharmaceutical Service Feb 7 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Crown Holdings, Waters and West Pharmaceutical Service, on Wednesday. HIGHLIGHTS * Chipotle Mexican Grill Inc CMG.N : TD Cowen raises target price to $2,900 from $2,650 * Crown Holdings Inc CCK.N : JP Morgan raises to overweight from neutral * Palantir Technologies Inc PLTR.N : Jefferies rais
A
A
B
C
C
C
C
F
G
A
C
W
A
A
A
C
C

U.S. Apellis Pharmaceuticals, Saia, Tesla

U.S. RESEARCH ROUNDUP-Apellis Pharmaceuticals, Saia, Tesla Feb 5 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Apellis Pharmaceuticals, Saia and Tesla, on Monday. HIGHLIGHTS * Apellis Pharmaceuticals Inc APLS.O : Jefferies raises to buy from hold * Charter Communications Inc CHTR.O : JP Morgan cuts to neutral from overweight * Lancaster Colony Corp LANC.O : Stephens cuts to equal weight from overweight * Saia Inc SA
A
B
B
C
C
C
P
R
T
W
C
C
C
C
C
D
E

Church & Dwight Co Inc reports results for the quarter ended in December - Earnings Summary

Church & Dwight Co Inc reports results for the quarter ended in December - Earnings Summary Church & Dwight Co Inc CHD.N reported quarterly adjusted earnings of 65 cents​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of -67 cents. The mean expectation of eighteen analysts for the quarter was for earnings of 65 cents per share.
C

Condom maker Church & Dwight sees bullish 2024 sales on resilient demand

Condom maker Church & Dwight sees bullish 2024 sales on resilient demand Feb 2 (Reuters) - Church & Dwight CHD.N projected its annual net sales forecast above market estimates after posting upbeat fourth-quarter revenue on Friday, boosted by higher prices and resilient demand for its household and personal-care products. The New Jersey-based company sees 2024 reported net sales to grow between 4% and 5%, versus analysts' estimates of growth of 3.4% to $6.05 billion.
C

Church & Dwight Q4 Adjusted EPS USD 0.65 Vs. IBES Estimate USD 0.65

BRIEF-Church & Dwight Q4 Adjusted EPS USD 0.65 Vs. IBES Estimate USD 0.65 Feb 02 (Reuters) - Church & Dwight Q4 net income USD 153.7 million. Q4 EPS USD 0.62 Q4 gross profit USD 681.3 million Q4 pretax profit USD 195.2 million Q4 sales USD 1,528 million vs. IBES estimate USD 1,512 million Q4 operating income USD 216.1 million
C

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.